The research concludes that there is an increased risk of pancreatitis, gastroparesis, and bowel obstruction with the use of the drugs
doi:10.1039/d1fo02021h 228
The biggest worry is whether the drug moves into breast milk
Food and Drug Administration (FDA) for use in individuals with obesity and those who are overweight
[19] Los agonistas del receptor GLP-1, como la semaglutida y la liraglutida, suelen causar efectos adversos gastrointestinales como nuseas, vmitos, diarrea, estreimiento y molestias abdominales, especialmente durante el aumento de la dosis
In some cases, starting with Compounded Semaglutide Injection at the lowest dose ($189/mo) allows your system to acclimate gradually, minimizing digestive disruptions